Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
8.25
+0.07 (0.86%)
At close: Dec 20, 2024, 4:00 PM
8.27
+0.02 (0.24%)
After-hours: Dec 20, 2024, 7:53 PM EST
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending September 30, 2024, a decrease of -98.62%. This brings the company's revenue in the last twelve months to $52.00K, down -81.36% year-over-year. In the year 2023, Altimmune had annual revenue of $426.00K, down -726.47%.
Revenue (ttm)
$52.00K
Revenue Growth
-81.36%
P/S Ratio
n/a
Revenue / Employee
$881
Employees
59
Market Cap
586.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 1.45B |
Varex Imaging | 811.00M |
Fulgent Genetics | 277.76M |
Surmodics | 126.08M |
GRAIL | 117.67M |
Simulations Plus | 70.01M |
Capricor Therapeutics | 23.23M |
ALT News
- 2 days ago - Altimmune Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 6 days ago - Altimmune 2025: Redefining Obesity And MASH Treatment - Seeking Alpha
- 25 days ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - GlobeNewsWire
- 5 weeks ago - Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge - Seeking Alpha
- 5 weeks ago - Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health - Seeking Alpha
- 5 weeks ago - Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire